Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's ANDA activity

Executive Summary

Generic Drugs Division ANDA "actions," including approvals, increased from 2,149 in 1984 to 5,379 in 1985 to 7,430 in 1986, according to agency data distributed at a Nov. 3-4 Pharmaceutical Manufacturers Association meeting. Actual ANDA approvals during the same three years increased from 382 to 389 to 616. Original ANDAs filed with FDA jumped from 470 in 1984 (when the post-1962 ANDA/patent extension law was enacted) to 1,069 in 1985 and 1,062 in 1986; 814 of the ANDA filed in 1986 have been for post-1962 products. Post-1962 approvals have been granted to 14 brandname and 41 generic drug manufacturers since the law was passed. Eight of the generic firms received first-ever post-1962 ANDAs.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010993

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel